Q4 2025 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2026-02-17 · accession 0001388325-26-000007
$1.29B
Reported value
24
Positions
2025-12-31
Period end
The Brief · Novo Holdings A/S · Q4 2025
AI · grounded in 13F
Novo Holdings A/S closed its position in VTI, reducing exposure by $340.8M. The fund also exited positions in 2GH and RXRX, totaling over $109M in sales. Offsetting these exits, the fund established a new position in MPLT worth $64.8M and increased its stake in FDMT by 82.5%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 11271J107 | BN | BROOKFIELD CORP | $160.4M | 12.5% | 3,496,245 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $132.8M | 10.3% | 5,350,000 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $121.9M | 9.47% | 113,946 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $99.8M | 7.75% | 1,264,028 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $87.5M | 6.79% | 330,187 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $75.6M | 5.87% | 1,625,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $74.1M | 5.75% | 2,380,000 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $64.8M | 5.03% | 3,686,622 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $52.6M | 4.09% | 1,450,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $48.6M | 3.77% | 1,750,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $43.0M | 3.34% | 570,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $42.3M | 3.28% | 916,160 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $39.2M | 3.05% | 660,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $39.1M | 3.03% | 1,942,142 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $37.7M | 2.93% | 257,327 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $34.8M | 2.70% | 200,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $32.6M | 2.53% | 1,200,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $27.4M | 2.13% | 3,650,737 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $24.6M | 1.91% | 1,961,317 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $22.8M | 1.77% | 1,480,000 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $20.3M | 1.58% | 2,305,000 | Common | SOLE |
| 51655R200 | LNZA | LANZATECH GLOBAL INC | $2.2M | 0.17% | 158,148 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $2.1M | 0.16% | 441,558 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $1.5M | 0.12% | 2,512,453 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.